These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17766199)

  • 1. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
    Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
    Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
    JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
    Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
    Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors.
    Pozlep B; Meleh M; Kobal B; Verdenik I; Osredkar J; Kralj LZ; Meden-Vrtovec H
    Eur J Gynaecol Oncol; 2007; 28(5):394-9. PubMed ID: 17966220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid: an ovarian cancer marker.
    Sedláková I; Vávrová J; Tosner J; Hanousek L
    Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors.
    Tokumura A; Tominaga K; Yasuda K; Kanzaki H; Kogure K; Fukuzawa K
    Cancer; 2002 Jan; 94(1):141-51. PubMed ID: 11815970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lysophosphatidic acid in ovarian cancer patients].
    Sedlákova I; Vávrová J; Tosner J; Hanousek L
    Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
    Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
    J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the Ovarian Cancer Biomarker Lysophosphatidic Acid in Serum.
    De La Franier B; Thompson M
    Biosensors (Basel); 2020 Feb; 10(2):. PubMed ID: 32075013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of lysophosphatidic acids by capillary electrophoresis with indirect ultraviolet detection.
    Chen YL; Xu Y
    J Chromatogr B Biomed Sci Appl; 2001 Apr; 753(2):355-63. PubMed ID: 11334351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative determination of lysophosphatidic acid by LC/ESI/MS/MS employing a reversed phase HPLC column.
    Shan L; Jaffe K; Li S; Davis L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 864(1-2):22-8. PubMed ID: 18262478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses.
    Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y
    Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
    Sedláková I; Vávrová J; Tošner J; Hanousek L
    Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for quantifying lysophosphatidic acid in body fluids: a review.
    Jesionowska A; Cecerska E; Dolegowska B
    Anal Biochem; 2014 May; 453():38-43. PubMed ID: 24613261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophospholipids are potential biomarkers of ovarian cancer.
    Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.
    Li YY; Zhang WC; Zhang JL; Zheng CJ; Zhu H; Yu HM; Fan LM
    Lipids Health Dis; 2015 Jul; 14():72. PubMed ID: 26174150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.
    Cao L; Zhang Y; Fu Z; Dong L; Yang S; Meng W; Li Y; Zhang W; Zhang J; Zheng C; Zhu H; Fan L
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1951-8. PubMed ID: 26472266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
    Lu Z; Chen Y; Hu Z; Hu C
    Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma lysophosphatidic acid concentration and ovarian cancer.
    Baker DL; Morrison P; Miller B; Riely CA; Tolley B; Westermann AM; Bonfrer JM; Bais E; Moolenaar WH; Tigyi G
    JAMA; 2002 Jun; 287(23):3081-2. PubMed ID: 12069669
    [No Abstract]   [Full Text] [Related]  

  • 20. Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity.
    Tokumura A; Kume T; Fukuzawa K; Tahara M; Tasaka K; Aoki J; Arai H; Yasuda K; Kanzaki H
    Life Sci; 2007 Apr; 80(18):1641-9. PubMed ID: 17367815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.